Qiming Venture Partners

Developer of artificial meat. The company develops artificial meat and cultured alternative protein products at the cellular level, committing to creating a new solution for future food supply.

Guangzhou Chaoshiji Biotechnology Co., Ltd. (Chaoshiji Technologies) is a high-tech company specializing in the creation and deployment of super-resolution imaging devices for living cells. R&D, production, sales, after-sales, and technical output services for various types of super-resolution optical microscopes are the primary activities. Among the services offered are customized cell sample generation, customized cell sample high-throughput detection, customized cell sample imaging studies, and customized image post-processing and quantitative analysis.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Zhangjiagang Onechip Bio-Technology Co.,Ltd. develops and manufactures new generations of biochemical sensor chips and nanomaterials for various applications. It offers pH chip, such as nano-electrodes; biochips; and nanometer materials, including oil absorption and sustained release products and battery protection products. The company’s products are based on the nanoscale electronic biochemical sensors and nanomaterial technologies. It sells its products online. Zhangjiagang Onechip Bio-Technology Co.,Ltd. was founded in 2014 and is based in Zhangjiagang, China.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.

Genlight is a company based in Hangzhou, China, that specializes in developing advanced treatment solutions for epilepsy and other neurological disorders. The organization focuses on innovative technologies in the field of brain science and neurosurgery, creating laser medical equipment designed to improve patient outcomes. Genlight's offerings include brain-computer control technology, deep brain nerve stimulation with full-cranial implantation, brain computer chips, and a minimally invasive surgery system guided by magnetic resonance. These high-tech solutions aim to provide patients with effective and cutting-edge surgical options for neurological conditions.

Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company's primary offerings include modified nucleotides, unnatural amino acids, heterocycles, and fluorescent and labeling reagents. Okeanos supplies these products to leading pharmaceutical companies, earning a strong reputation for quality and reliability. The firm focuses on providing clients with a diverse range of chemical compounds and biochemical reagents, particularly in the realms of sequencing and synthetic biology.

Atom Semiconductor is a scientific and technological enterprise focusing on digital sensor design. Atom Semiconductor was founded in 2020.

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.

Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Developer of Tumor-treating Fields technology. The company's products are focused on delivering diagnostic and minimally invasive treatment tools for various brain cancers, enabling healthcare professionals to more effectively treat patients.

Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Nanjing Chuhang Technology Co., Ltd. specializes in the development and production of millimeter-wave radar technology for advanced driver assistance systems (ADAS) and autonomous driving. The company offers a range of products, including 77 GHz angle radars and forward midrange radars, which are utilized in applications such as blind zone detection, automatic parking, emergency braking, adaptive cruise control, forward crossing warning, heartbeat breath detection, gesture recognition, and smart agriculture. Founded in 2018 and headquartered in Nanjing, China, Chuhang Tech has expanded its presence with subsidiaries in several Chinese cities, as well as in Stuttgart, Germany.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Nanjing Chuhang Technology Co., Ltd. specializes in the development and production of millimeter-wave radar technology for advanced driver assistance systems (ADAS) and autonomous driving. The company offers a range of products, including 77 GHz angle radars and forward midrange radars, which are utilized in applications such as blind zone detection, automatic parking, emergency braking, adaptive cruise control, forward crossing warning, heartbeat breath detection, gesture recognition, and smart agriculture. Founded in 2018 and headquartered in Nanjing, China, Chuhang Tech has expanded its presence with subsidiaries in several Chinese cities, as well as in Stuttgart, Germany.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

NASN Automotive Electronics is committed to providing advanced and complete chassis electronic control products, ADAS and autonomous driving related core technologies for the Chinese automotive market. The main products include NBooster intelligent brake system, brushless electric steering EPS controller and wire control system. It is a scientific and technological innovation enterprise integrating R&D, production and sales.

NASN Automotive Electronics is committed to providing advanced and complete chassis electronic control products, ADAS and autonomous driving related core technologies for the Chinese automotive market. The main products include NBooster intelligent brake system, brushless electric steering EPS controller and wire control system. It is a scientific and technological innovation enterprise integrating R&D, production and sales.

MicroPoint Bioscience, Inc. (微点生物) is a Chinese company dedicated to biochip research and development. The company offers a product series, Lab On a Chip, which is based on micro-electronic mechanical technologies. MicroPoint Biosciences customizes demanded products and services for customers in areas of human health such as medicine, environmental protection, food safety, scientific research, and other application areas. In the area of medicine, MicroPoint Company's bedside immediate diagnosis chip and examination instrument provides low-cost resolutions for early diagnosis and the process monitoring of vascular diseases, tumors, emergency treatments, and operations.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

SceneRay Corporation, Limited is a medical device company based in Suzhou, China, specializing in the design, development, and distribution of neuromodulation devices. The company offers a range of products, including a deep brain stimulation system that features an implantable neuro-stimulator, patient controller, and various accessories. Additionally, SceneRay develops spinal cord stimulation and sacral nerve stimulation systems. The team at SceneRay comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, and the company holds numerous patents in this field. Committed to advancing neuromodulation solutions, SceneRay aims to provide patients with high-quality and effective treatments.

OPUS develops clinically applicable tissue engineering products and treatments.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is an integrated pharmaceutical group based in Beijing, China, with an additional office in Haikou. Founded in 2005, the company specializes in both generic and patented therapies, focusing on a broad range of products including radiopharmaceuticals and biopharmaceuticals. Sinotau manufactures various medications, including antibiotics, vitamins, hormones, and treatments for oncology, digestive, cardiovascular, diabetes, respiratory, and gynecological conditions, available in tablets, capsules, and granules. The company also serves the biotechnology industry by developing advanced generic drugs and offers expertise in medicinal chemical synthesis, drug analysis, pharmaceutical preparations, and drug registration, leveraging advanced monoclonal antibody technologies.

Sinocelltech Group Limited is a biotechnology company based in Beijing, China, specializing in the development and production of biopharmaceutical products, including recombinant proteins, monoclonal antibodies, and vaccines. The company has established advanced technology platforms that encompass protein expression vectors, cell line development, serum-free medium development, and stoichiometrically controlled fed-batch cell culture. Sinocelltech focuses on the industrialization of its products, offering capabilities in stable CHO cell line development, cell banking, and certification, as well as optimization and large-scale production processes. The company's mission is to enhance access to life-saving biological medications by continually improving manufacturing technologies to reduce development and production costs.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Shenogen Pharma Group is a drug discovery and development company.

VINNO Technology (Suzhou) Co., Ltd., founded in 2010 and located in Suzhou, China, specializes in the development and manufacture of high-end color Doppler ultrasound diagnostic systems. The company provides a range of medical tools, including consoles, portable devices, general imaging products, and equipment for cardiovascular and women's healthcare applications. VINNO aims to enhance diagnostic processes in hospitals and clinics, enabling medical professionals to deliver accurate and efficient patient care. In addition to its product offerings, the company supports its clients with pre-sale consultations, post-sale services, and various training programs. With a focus on innovation and global expansion, VINNO seeks collaborations with international partners to further advance its medical technology solutions.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Zhejiang Nurotron Biotechnology Co., Ltd. specializes in the development, manufacturing, and supply of nerve electronic products, focusing primarily on cochlear implant systems. The company's flagship product line includes the Venus cochlear implant systems, which feature cochlear speech processors and implants designed for individuals with severe to profound hearing loss. In addition to its core offerings, Nurotron provides accessories and online consulting services related to its products. Founded in 2006, the company is headquartered in Hangzhou, China, with a dedicated research and development center located in California, USA. Its efforts encompass the research and development of advanced cochlear systems and the clinical application of auditory brainstem implants, aimed at enhancing the accessibility and effectiveness of hearing solutions.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Shenogen Pharma Group is a drug discovery and development company.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

LanzaTech, Inc. is a carbon recycling company based in Skokie, Illinois, with additional offices in Roselle, Illinois; Shanghai, China; and Gurgaon, India. Founded in 2005, the company specializes in producing fuel ethanol from renewable non-food resources, including industrial flue gases and waste gases generated from the gasification of municipal solid waste and biomass. LanzaTech's innovative technology enables the conversion of carbon emissions from sources like steel mills into valuable products, such as sustainable fuels and chemicals, thus contributing to a circular carbon economy. By recycling carbon from various waste streams, LanzaTech aims to reduce global CO2 emissions significantly and displace a substantial portion of crude oil use, ultimately transforming waste carbon into essential building blocks for consumer goods.

Zhejiang Nurotron Biotechnology Co., Ltd. specializes in the development, manufacturing, and supply of nerve electronic products, focusing primarily on cochlear implant systems. The company's flagship product line includes the Venus cochlear implant systems, which feature cochlear speech processors and implants designed for individuals with severe to profound hearing loss. In addition to its core offerings, Nurotron provides accessories and online consulting services related to its products. Founded in 2006, the company is headquartered in Hangzhou, China, with a dedicated research and development center located in California, USA. Its efforts encompass the research and development of advanced cochlear systems and the clinical application of auditory brainstem implants, aimed at enhancing the accessibility and effectiveness of hearing solutions.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

VINNO Technology (Suzhou) Co., Ltd., founded in 2010 and located in Suzhou, China, specializes in the development and manufacture of high-end color Doppler ultrasound diagnostic systems. The company provides a range of medical tools, including consoles, portable devices, general imaging products, and equipment for cardiovascular and women's healthcare applications. VINNO aims to enhance diagnostic processes in hospitals and clinics, enabling medical professionals to deliver accurate and efficient patient care. In addition to its product offerings, the company supports its clients with pre-sale consultations, post-sale services, and various training programs. With a focus on innovation and global expansion, VINNO seeks collaborations with international partners to further advance its medical technology solutions.

Zhejiang Nurotron Biotechnology Co., Ltd. specializes in the development, manufacturing, and supply of nerve electronic products, focusing primarily on cochlear implant systems. The company's flagship product line includes the Venus cochlear implant systems, which feature cochlear speech processors and implants designed for individuals with severe to profound hearing loss. In addition to its core offerings, Nurotron provides accessories and online consulting services related to its products. Founded in 2006, the company is headquartered in Hangzhou, China, with a dedicated research and development center located in California, USA. Its efforts encompass the research and development of advanced cochlear systems and the clinical application of auditory brainstem implants, aimed at enhancing the accessibility and effectiveness of hearing solutions.

LanzaTech, Inc. is a carbon recycling company based in Skokie, Illinois, with additional offices in Roselle, Illinois; Shanghai, China; and Gurgaon, India. Founded in 2005, the company specializes in producing fuel ethanol from renewable non-food resources, including industrial flue gases and waste gases generated from the gasification of municipal solid waste and biomass. LanzaTech's innovative technology enables the conversion of carbon emissions from sources like steel mills into valuable products, such as sustainable fuels and chemicals, thus contributing to a circular carbon economy. By recycling carbon from various waste streams, LanzaTech aims to reduce global CO2 emissions significantly and displace a substantial portion of crude oil use, ultimately transforming waste carbon into essential building blocks for consumer goods.

Shenogen Pharma Group is a drug discovery and development company.

Shenogen Pharma Group is a drug discovery and development company.

VINNO Technology (Suzhou) Co., Ltd., founded in 2010 and located in Suzhou, China, specializes in the development and manufacture of high-end color Doppler ultrasound diagnostic systems. The company provides a range of medical tools, including consoles, portable devices, general imaging products, and equipment for cardiovascular and women's healthcare applications. VINNO aims to enhance diagnostic processes in hospitals and clinics, enabling medical professionals to deliver accurate and efficient patient care. In addition to its product offerings, the company supports its clients with pre-sale consultations, post-sale services, and various training programs. With a focus on innovation and global expansion, VINNO seeks collaborations with international partners to further advance its medical technology solutions.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Zhejiang Nurotron Biotechnology Co., Ltd. specializes in the development, manufacturing, and supply of nerve electronic products, focusing primarily on cochlear implant systems. The company's flagship product line includes the Venus cochlear implant systems, which feature cochlear speech processors and implants designed for individuals with severe to profound hearing loss. In addition to its core offerings, Nurotron provides accessories and online consulting services related to its products. Founded in 2006, the company is headquartered in Hangzhou, China, with a dedicated research and development center located in California, USA. Its efforts encompass the research and development of advanced cochlear systems and the clinical application of auditory brainstem implants, aimed at enhancing the accessibility and effectiveness of hearing solutions.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

LanzaTech, Inc. is a carbon recycling company based in Skokie, Illinois, with additional offices in Roselle, Illinois; Shanghai, China; and Gurgaon, India. Founded in 2005, the company specializes in producing fuel ethanol from renewable non-food resources, including industrial flue gases and waste gases generated from the gasification of municipal solid waste and biomass. LanzaTech's innovative technology enables the conversion of carbon emissions from sources like steel mills into valuable products, such as sustainable fuels and chemicals, thus contributing to a circular carbon economy. By recycling carbon from various waste streams, LanzaTech aims to reduce global CO2 emissions significantly and displace a substantial portion of crude oil use, ultimately transforming waste carbon into essential building blocks for consumer goods.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.